CELLDEX THERAPEUTICS INC (CLDX) Fundamental Analysis & Valuation

NASDAQ:CLDX • US15117B2025

Current stock price

32.59 USD
+0.35 (+1.09%)
At close:
32.59 USD
0 (0%)
After Hours:

This CLDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CLDX Profitability Analysis

1.1 Basic Checks

  • In the past year CLDX has reported negative net income.
  • In the past year CLDX has reported a negative cash flow from operations.
  • CLDX had negative earnings in each of the past 5 years.
  • In the past 5 years CLDX always reported negative operating cash flow.
CLDX Yearly Net Income VS EBIT VS OCF VS FCFCLDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • CLDX has a Return On Assets (-44.38%) which is comparable to the rest of the industry.
  • With a decent Return On Equity value of -49.08%, CLDX is doing good in the industry, outperforming 62.79% of the companies in the same industry.
Industry RankSector Rank
ROA -44.38%
ROE -49.08%
ROIC N/A
ROA(3y)-31.56%
ROA(5y)-28.48%
ROE(3y)-34.39%
ROE(5y)-30.88%
ROIC(3y)N/A
ROIC(5y)N/A
CLDX Yearly ROA, ROE, ROICCLDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CLDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDX Yearly Profit, Operating, Gross MarginsCLDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CLDX Health Analysis

2.1 Basic Checks

  • CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CLDX has more shares outstanding
  • CLDX has more shares outstanding than it did 5 years ago.
  • CLDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLDX Yearly Shares OutstandingCLDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CLDX Yearly Total Debt VS Total AssetsCLDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 21.66 indicates that CLDX is not in any danger for bankruptcy at the moment.
  • CLDX has a Altman-Z score of 21.66. This is amongst the best in the industry. CLDX outperforms 88.37% of its industry peers.
  • CLDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.66
ROIC/WACCN/A
WACC9.15%
CLDX Yearly LT Debt VS Equity VS FCFCLDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 10.49 indicates that CLDX has no problem at all paying its short term obligations.
  • CLDX has a better Current ratio (10.49) than 81.40% of its industry peers.
  • A Quick Ratio of 10.49 indicates that CLDX has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 10.49, CLDX belongs to the best of the industry, outperforming 81.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.49
Quick Ratio 10.49
CLDX Yearly Current Assets VS Current LiabilitesCLDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CLDX Growth Analysis

3.1 Past

  • The earnings per share for CLDX have decreased strongly by -58.78% in the last year.
  • CLDX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -77.98%.
  • The Revenue for CLDX have been decreasing by -26.94% on average. This is quite bad
EPS 1Y (TTM)-58.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.83%
Revenue 1Y (TTM)-77.98%
Revenue growth 3Y-13.17%
Revenue growth 5Y-26.94%
Sales Q2Q%-89.7%

3.2 Future

  • Based on estimates for the next years, CLDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.98% on average per year.
  • CLDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 223.60% yearly.
EPS Next Y-26.02%
EPS Next 2Y-12.21%
EPS Next 3Y2.88%
EPS Next 5Y19.98%
Revenue Next Year27.53%
Revenue Next 2Y106.96%
Revenue Next 3Y285.36%
Revenue Next 5Y223.6%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLDX Yearly Revenue VS EstimatesCLDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
CLDX Yearly EPS VS EstimatesCLDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. CLDX Valuation Analysis

4.1 Price/Earnings Ratio

  • CLDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDX Price Earnings VS Forward Price EarningsCLDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDX Per share dataCLDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.21%
EPS Next 3Y2.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLDX Dividend Analysis

5.1 Amount

  • CLDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLDX Fundamentals: All Metrics, Ratios and Statistics

CELLDEX THERAPEUTICS INC

NASDAQ:CLDX (4/13/2026, 8:16:55 PM)

After market: 32.59 0 (0%)

32.59

+0.35 (+1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-30
Inst Owners109.92%
Inst Owner Change0.01%
Ins Owners0.21%
Ins Owner Change2.15%
Market Cap2.51B
Revenue(TTM)1.55M
Net Income(TTM)-258.76M
Analysts82.73
Price Target55.42 (70.05%)
Short Float %13.92%
Short Ratio10.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.26%
Min EPS beat(2)-18.58%
Max EPS beat(2)-9.94%
EPS beat(4)1
Avg EPS beat(4)-7.77%
Min EPS beat(4)-18.58%
Max EPS beat(4)2.62%
EPS beat(8)5
Avg EPS beat(8)1.46%
EPS beat(12)7
Avg EPS beat(12)-0.55%
EPS beat(16)9
Avg EPS beat(16)-0.98%
Revenue beat(2)0
Avg Revenue beat(2)-95.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)-91.97%
Revenue beat(4)0
Avg Revenue beat(4)-63.94%
Min Revenue beat(4)-100%
Max Revenue beat(4)-28.92%
Revenue beat(8)3
Avg Revenue beat(8)17.55%
Revenue beat(12)6
Avg Revenue beat(12)63.38%
Revenue beat(16)8
Avg Revenue beat(16)71.19%
PT rev (1m)8.31%
PT rev (3m)1.83%
EPS NQ rev (1m)-1.95%
EPS NQ rev (3m)-6.43%
EPS NY rev (1m)-3.06%
EPS NY rev (3m)-9.69%
Revenue NQ rev (1m)-12.55%
Revenue NQ rev (3m)49.11%
Revenue NY rev (1m)6.98%
Revenue NY rev (3m)2.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1620.86
P/FCF N/A
P/OCF N/A
P/B 4.75
P/tB 5.01
EV/EBITDA N/A
EPS(TTM)-3.89
EYN/A
EPS(NY)-4.9
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0.02
BVpS6.86
TBVpS6.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.38%
ROE -49.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.56%
ROA(5y)-28.48%
ROE(3y)-34.39%
ROE(5y)-30.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.3%
Cap/Sales 175.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.49
Quick Ratio 10.49
Altman-Z 21.66
F-Score2
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)67.05%
Cap/Depr(5y)60.99%
Cap/Sales(3y)76.47%
Cap/Sales(5y)66.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.83%
EPS Next Y-26.02%
EPS Next 2Y-12.21%
EPS Next 3Y2.88%
EPS Next 5Y19.98%
Revenue 1Y (TTM)-77.98%
Revenue growth 3Y-13.17%
Revenue growth 5Y-26.94%
Sales Q2Q%-89.7%
Revenue Next Year27.53%
Revenue Next 2Y106.96%
Revenue Next 3Y285.36%
Revenue Next 5Y223.6%
EBIT growth 1Y-47.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.96%
EBIT Next 3Y0.04%
EBIT Next 5YN/A
FCF growth 1Y-33.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.7%
OCF growth 3YN/A
OCF growth 5YN/A

CELLDEX THERAPEUTICS INC / CLDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CELLDEX THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to CLDX.


Can you provide the valuation status for CELLDEX THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CELLDEX THERAPEUTICS INC (CLDX). This can be considered as Overvalued.


How profitable is CELLDEX THERAPEUTICS INC (CLDX) stock?

CELLDEX THERAPEUTICS INC (CLDX) has a profitability rating of 1 / 10.


What is the financial health of CELLDEX THERAPEUTICS INC (CLDX) stock?

The financial health rating of CELLDEX THERAPEUTICS INC (CLDX) is 8 / 10.


What is the expected EPS growth for CELLDEX THERAPEUTICS INC (CLDX) stock?

The Earnings per Share (EPS) of CELLDEX THERAPEUTICS INC (CLDX) is expected to decline by -26.02% in the next year.